FDA approves adjuvant pembrolizumab for intermediate-high risk kidney cancer

The Food and Drug administration (FDA) in the USA has approved pembrolizumab for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate or high risk of recurrence following nephrectomy, or for RCC patients after having a nephrectomy and removal of metastases. Adjuvant therapy┬áis medication that is given in addition to surgery to […]

read more

Pazopanib for poor risk kidney cancer patients

Pazopanib is used for first-line metastatic RCC treatment, but the data for poor-risk patients are scarce. The FLIPPER study was designed to determine the safety and efficacy of first-line pazopanib in poor-risk patients with metastatic RCC. FLIPPER was a single-arm, open-label, phase IV trial involving 60 patients with poor-risk metastatic mRCC. All patients were treated […]

read more

Selecting therapy for poor-risk advanced kidney cancer

In this video interview, Dr Earle Burgess from the Levine Cancer Centre in the USA talks about the factors that are considered when selecting therapy for patients with poor-risk advanced renal cell carcinoma (RCC). Such factors include the risk status of the patient, burden or sites of disease, co-morbidities such as hypertension and cardiac disease, […]

read more
Showing all 3 results